Received Dec 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | UNK | — | — |
| FLUX | INFLUENZA (SEASONAL) (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | — |
experiencing symptoms of an infection after received covid and flu vaccinations 2 days ago low grade fevers, fatigue; experiencing symptoms of an infection after received covid and flu vaccinations 2 days ago low grade fevers, fatigue; experiencing symptoms of an infection after received covid and flu vaccinations 2 days ago low grade fevers, fatigue; symptoms have gotten worse (dermatitis atopic); eczema flare ups; This is a spontaneous report received from a Consumer or other non HCP from License Party. Other Case identifier(s): 2025SA236003 (Sanofi), AE-022009 (BIONTECH). A 5-year-old female patient (not pregnant) received BNT162b2 omicron (lp.8.1) (COMIRNATY (2025-2026 FORMULA)), on 17Nov2025 as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation; influenza vaccine (INFLUENZA VACCINE), on 17Nov2025 as dose number unknown, single for immunisation; dupilumab (DUPIXENT), first regimen since 28Mar2025 at 300 mg (300 mg q4w), second regimen since Nov2025 (Lot number: 5F001A, Expiration Date: 31Aug2026) at 300 mg (300 mg q4w) and third regimen since 2025 (ongoing) (Lot number: 4F582A, Expiration Date: 31Jan2027) at 300 mg (300 mg q4w), all subcutaneous for dermatitis atopic. The patient's relevant medical history included: "atopic dermatitis" (ongoing). Concomitant medication(s) included: ZYRTEC ALLERGY. The following information was reported: ECZEMA (non-serious) with onset 2025, outcome "unknown", described as "eczema flare ups"; DERMATITIS ATOPIC (non-serious) with onset 2025, outcome "unknown", described as "symptoms have gotten worse (dermatitis atopic)"; INFECTION (non-serious), PYREXIA (non-serious), FATIGUE (non-serious) all with onset 19Nov2025, outcome "unknown" and all described as "experiencing symptoms of an infection after received covid and flu vaccinations 2 days ago low grade fevers, fatigue". The action taken for dupilumab was unknown. Additional information: patient had no known drug allergy; no known environmental allergy; no known food allergy; no known latex allergy. In Nov2025 the patient experienced symptoms of an infection after received covid and flu vaccinations 2 days ago low grade fevers, fatigue following the first dose intake (batch number: 5F001A, expiry date on 31-Aug-2026) of DUPILUMAB; COVID-19 VACCINE and FLU VACCINE (Unknown INN). On an unknown date in 2025, the patient's symptoms have gotten worse (dermatitis atopic) (unknown latency) following the first dose intake (Batch number: 4F582A and expiry date: 31-Jan-2027) of DUPILUMAB. The patient's mother reported her daughter experiencing symptoms of an infection after received covid and flu vaccinations 2 days ago - low grade fevers, fatigue, and reported her experiencing recent eczema flare-ups. Corrective treatment: Not reported for all the events. Caregiver reported patients' symptoms have gotten worse and condition has no affect on sleep. No further detail provided. Therapy (Dupilumab): ongoing. DUPILUMAB (DUPIXENT); COVID-19 VACCINE (COVID-19 VACCINE) and FLU VACCINE was unknown for all the events. No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.
Atopic dermatitis
ZYRTEC ALLERGY; DUPIXENT